NCT00735267

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 468 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.

Detailed description

Termination reason: On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	PD 0332334	Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year

Timeline

• Start date: 2008-10-01
• Primary completion: 2009-04-01
• Completion: 2009-04-01
• First posted: 2008-08-14
• Last updated: 2012-11-16

Locations

93 sites across 1 country: United States